## Syngene International Limited (SYNGENE) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Syngene International Limited (SYNGENE) is a leading research, development, and manufacturing organization in the Healthcare Research Analytics & Technology industry.  Listed on the NSE on August 11, 2015, Syngene holds a strong position within its sector, known for its integrated services and global clientele.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price              | ₹844            | Closed down ₹5.95 (-0.70%)                                          |
| Percentage Change (PChange) | -0.70%          | Negative daily change, indicating bearish sentiment.                  |
| Pre-Open Activity          | ₹849.95 (IEP)   |  Pre-open price higher than closing price, suggesting potential recovery.  High buy volume at IEP. |
| Week High                   | ₹960.6          | Significant price increase during the week.                           |
| Week Low                    | ₹607.65         | Significant price drop during the week, indicating volatility.       |
| VWAP                       | ₹845.47         | Close to the closing price, suggesting relatively stable trading.     |
| Sector PE                  | 74.54           | Syngene's PE ratio is slightly lower than the sector average.       |
| Symbol PE                  | 71              | Indicates relatively lower valuation compared to the sector.         |
| Delivery Percentage        | 73.53%          | High delivery percentage suggests genuine buying interest.            |
| Market Depth               | Low              | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes Syngene's financial performance over the past five quarters:

| Quarter Ending      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | EPS (₹) |
|----------------------|--------------|---------------|-----------------------|---------|
| 30-Sep-2024          | 83,770       | 71,340        | 9,660                  | 2.41    |
| 30-Jun-2024          | 74,420       | 67,740        | 7,390                  | 1.84    |
| 31-Mar-2024          | 88,000       | 66,960        | 18,980                 | 4.73    |
| 31-Dec-2023          | 82,070       | 69,230        | 9,980                  | 2.49    |
| 30-Sep-2023          | 85,170       | 71,360        | 10,160                 | 2.53    |

**Analysis:** Revenue shows some fluctuation, but generally positive trend. Profit after tax and EPS show significant variation quarter-to-quarter, indicating potential volatility in earnings.  The March 2024 quarter shows exceptionally high profitability, which needs further investigation to determine if it's sustainable.

**4. Corporate Actions and Announcements:**

* **Dividends:** Syngene has a history of paying dividends, with a recent dividend of ₹1.25 per share (ex-date 28-Jun-2024).  This demonstrates a commitment to shareholder returns.
* **Bonus Issue:** A 1:1 bonus issue was implemented in June 2019.
* **Announcements:** Recent announcements primarily focus on analyst meetings and updates, suggesting active investor engagement.  A litigation disclosure was also made, which requires further investigation into its potential impact.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023     | 54.79                        | 44.72      | 0.48                           | 100.00    |
| 31-Dec-2023     | 54.79                        | 44.89      | 0.32                           | 100.00    |
| 31-Mar-2024     | 54.79                        | 44.90      | 0.31                           | 100.00    |
| 30-Jun-2024     | 54.72                        | 44.85      | 0.43                           | 100.00    |
| 30-Sep-2024     | 54.72                        | 44.94      | 0.34                           | 100.00    |

**Analysis:** Promoter holding remains relatively stable, indicating confidence in the company's prospects. Public shareholding shows minor fluctuations.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 31.33% further confirms this.  Risks include fluctuations in earnings, dependence on the pharmaceutical industry, and potential impacts from the disclosed litigation.  The low market depth adds to the volatility risk.

**7. Advantages of Buying the Stock:**

* Strong promoter holding.
* Consistent dividend payouts.
* Established position in a growing sector.
* Relatively lower PE ratio compared to the sector.

**8. Disadvantages and Risks:**

* High volatility.
* Inconsistent quarterly financial performance.
* Potential impact of ongoing litigation.
* Low market depth.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price drop and low market depth suggest caution.  Waiting for clearer price direction is advisable.
* **Medium-term (3 to 12 months): Buy.**  The long-term growth potential of the healthcare sector and Syngene's established position make it a potentially attractive investment.  However, monitor the litigation and financial performance closely.
* **Long-term (1 year and beyond): Buy.**  Syngene's fundamentals, consistent dividend payouts, and sector positioning suggest long-term growth potential.

**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Inconsistent quarterly performance, but generally positive revenue trend)
* Market Performance: 6/10 (High volatility, but strong promoter holding)
* Volatility and Risk: 5/10 (High volatility, low market depth, litigation risk)
* Corporate Actions & Governance: 8/10 (Consistent dividends, active investor engagement)
* Shareholding Patterns: 7/10 (Stable promoter holding)

**Analysis Score (out of 10): 9**

* Completeness and utilization of data: 10/10 (All provided data was used effectively)
* Accuracy and clarity of analysis: 9/10 (Analysis is clear and well-supported by data, but some aspects require further investigation)
* Professional formatting: 10/10 (Report is well-structured and easy to understand)


**11. Professional Recommendation Summary:**

Based on the analysis of Syngene's financial performance, market data, corporate actions, and shareholding patterns, the recommendation is to **Hold** in the short term, **Buy** in the medium term, and **Buy** in the long term.  The high volatility and low market depth necessitate a cautious short-term approach. However, the company's fundamentals, sector positioning, and dividend history support a positive outlook for medium-term and long-term investments.  Further investigation into the impact of the disclosed litigation is recommended before making any investment decision.
